Navigation Links
Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
Date:9/21/2010

FRANKLIN, Mass., Sept. 21 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that it is beginning a development program designed to create a new transdermal biosensor for continuous lactate monitoring to be used in critical care and sports medicine.  Echo is initiating this program based upon positive results seen in ex-vivo testing on humans undergoing exercise, using a needle-free continuous lactate monitoring biosensor.  

Lactate monitoring is important in diverse fields such as critical care medicine, sports medicine, exercise physiology and nutritional science.  In sports medicine, lactate threshold is an important indicator of muscular tolerance and, therefore, the performance of individual athletes.  Proper monitoring of lactate threshold will not only serve to increase performance but also decrease injuries for athletes.  Additionally, lactate monitoring is important in critically ill patients in shock as the amount of lactate produced is believed to correlate with oxygen deprivation, hypoperfusion, and the severity of shock.

"We are excited to begin yet another transdermal, continuous monitoring program, this one in lactate biosensing," stated Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics.  "Building upon the positive results that we have demonstrated with our initial indication of continuous glucose monitoring in critical care, continuous lactate monitoring is a logical extension of our research efforts. The initiation of this program demonstrates the robust platform our technology provides, extending well beyond the hospital and diabetes markets.  The results of our ex-vivo testing strongly suggest that we can effectively monitor lactate thresholds using our transdermal biosensor technology.  Leveraging our deep expertise in advanced skin permeation technology, we anticipate commencing additional programs over the coming year, building a significant pipeline of both transdermal biosensors and needle-free topical and systemic drug delivery products."

Dr. Mooney added, "Transdermal biosensors using our advanced skin permeation technology platform have the potential for significant and multiple applications.  With these results and our knowledge of the critical care market, lactate biosensing is an obvious addition to Echo's product development program.  We look forward to updating investors on all our programs, importantly on Symphony tCGM in the near future."  

About Echo TherapeuticsEcho is currently developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Patrick T. Mooney, M.D.

Jeffrey Stanlis

Media: Richard SternChairman and Chief Executive Officer

Partner, Hayden IR

Stern & Co.(508) 530-0329

(602) 476-1821

(212) 888-0044
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
2. CoDa Therapeutics NEXAGON® Wound Healing Gel Named to Windhovers Top 10 HOT SPACE Projects to Watch
3. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
4. Echo Therapeutics to Present at Prestigious Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference
5. Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Halozyme Therapeutics Announces Public Offering of Common Stock
8. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
9. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
10. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
11. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)... -- Global Immunology Market to 2022 - Large ... growth Summary Immune-mediated inflammatory diseases are ... affect 5–7% of western populations. Although they are ... key patient demographics, they are pathophysiologically linked, being ... inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a ...
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
Breaking Medicine Technology:
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... 05, 2016 , ... Pivot Point Consulting, a leading national ... & Services for HIT Implementation Support & Staffing report with an outstanding score ... by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Colorize ... from on one drop zone to the next using Colorize's dynamic moving camera. Colorize ... project. This package includes a 3D slideshow environment with 1 to 5 focus points ...
(Date:2/5/2016)... ... 05, 2016 , ... Calls Blacklist has just been updated by mobile app ... the developer has fixed known bugs within the app. Calls Blacklist allows its users ... not consuming any of their device’s battery power or memory. It provides a powerful ...
Breaking Medicine News(10 mins):